We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

Cyclic Peptide

Intracellular Protein-Protein Interactions (PPIs) are tough targets for both small molecules and antibody drugs, while conventional peptides are neither orally available nor cell-permeable. With advanced biotechnology and chemistry, we successfully established a proprietary library of orally available and cell-permeable cyclic peptides and screening technology. Our first mid-size molecule drug, LUNA18, is being tested in clinical studies, and we have multiple cyclic peptide projects in the drug discovery stage.

< Back